Zurueck zur Suche

Reporte zur Charge UJ372AA

Verknuepft ueber VAERS_ID mit VAERSDATA, Vax und Symptoms

8Reporte angezeigt
0Todesfaelle
0Hospitalisiert
0Lebensbedrohlich
0Bleibende Schaeden
MD 2 NY 2 OH 1 CA 1 MA 1 VA 1

VAERS 1417861

SANOFI PASTEUR · YELLOW FEVER (YF-VAX) · Charge UJ372AA

moderat
Staat
MD
Alter
2,0
Geschlecht
F
Eingang
22.06.2021
Impfdatum
10.06.2021
Beginn
14.06.2021
Tage bis Beginn
4,0
Dosis
UNK
Route/Site
SC / RL
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: nein
Alopecia Condition aggravated

Symptomtext

Patient's parents noticed the onset of hair loss starting 6/14/21, and report no other symptoms. The hair loss is on-going as of today. The patient?s father reports a history of 2 prior episodes of similar hair loss, the first occurring in July/August of 2020 (approximately 85% total hair loss) and the 2nd episode occurring in December 2020 (with approximately 40% total hair loss). During those 2 prior episodes, the patient was evaluated by her pediatrician and a pediatric dermatologist. A diagnosis of alopecia (of likely auto-immune etiology) was made and topical steroids were prescribed.

Weitere VAERSDATA-Felder
Praegender Schweregrund
Condition aggravated
Hospital-Tage
-
Labordaten
None known
Aktuelle Erkrankungen
None
Vorgeschichte
None known
Andere Medikamente
None
Allergien
None known
Vorherige Impfungen
-

VAERS 1526009

SANOFI PASTEUR · YELLOW FEVER (YF-VAX) · Charge UJ372AA

mild
Staat
NY
Alter
-
Geschlecht
F
Eingang
09.07.2022
Impfdatum
20.07.2021
Beginn
22.07.2021
Tage bis Beginn
2,0
Dosis
1
Route/Site
OT / RA
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: ja
Injection site erythema Injection site pain Injection site warmth Laboratory test normal

Symptomtext

RabAvert and YF-Vax administered at the same site; Pt. had redness, warmth and soreness at the injection site; Pt. had redness, warmth and soreness at the injection site; Pt. had redness, warmth and soreness at the injection site; Case reference number US-BN-2021-002299, initially downloaded from Vaccine Adverse Event Reporting System (VAERS) on 27-Sep-2021, is a spontaneous case received from consumer via health authority (VAERS ID: 1526009-1) and concerns a 64-year-old female patient. The patient's medical history details were not provided. The patient's concomitant medications included Amitiza (lubiprostone), Synthyroid (Levothyroxine sodium), simvastatin and Myrbetriq (Mirabegron). On 20-Jul-2021, patient was vaccinated with the first dose of RabAvert (Inactivated Rabies Virus Vaccine; batch number: ARBA571B), at an unknown dose, administered intramuscularly in the right arm, for an unknown indication. On the same date, the patient was vaccinated with the co-suspect YF-VAX (Yellow Fever Vaccine Live; batch number: UJ372AA), at an unknown dose, administered subcutaneously in the right arm, for an unknown indication (explicitly codes as ?Vaccination error'). On 22-Jul-2021 (also reported as on 23-Jul-2021), the patient experienced redness, warmth and soreness at the injection site. It was reported that the physician prescribed the patient Kepflex 500mg, BID for a five day course, although the patient didn't start the medication. On 24-Jul-2021, the patient visited Emergency Department, where she was prescribed Doxycycline 100 mg BID and had laboratory tests performed, with results reported as laboratory test normal. It was reported that the patient started with the Doxycycline medication. On 27-Jul-2021, the patient visited the clinic again, and it was reported that on examination the redness was lighter in colour, but that it spread a little bit more. On an unspecified date, the patient recovered from the events of injection site redness, injection site warmth and injection site pain. The case was assessed as not serious. Causality assessment was not provided. No further information was provided.; Reporter's Comments: Injection site erythema and injection site pain are listed for RabAvert according to the PI and Prescriber Information, whilst injection site warmth is unlisted. Vaccination error is listed per convention. The patient was vaccinated with the first dose of RabAvert administered intramuscularly in the right arm, and on the same day, the patient was vaccinated with the co-suspect YF-VAX (Yellow Fever Vaccine Live) administered in the right arm, which is considered vaccination error. The patient experienced injection site erythema, injection site pain and injection site warmth two days after vaccination. The major confounding factor for the events is co-suspect vaccine (YF-VAX), administered on the same day. However, due to plausible temporal relationship and since contributory role of RabAvert cannot be excluded, the causality for the events of injection site erythema, injection site pain and injection site warmth is assessed as possibly related to the suspect vaccine. Vaccination error is not related to the suspect product, but to a decision of the prescribing physician. This case is considered non-serious.; Sender's Comments: Injection site erythema and injection site pain are listed for RabAvert according to the PI and Prescriber Information, whilst injection site warmth is unlisted. Vaccination error is listed per convention. The patient was vaccinated with the first dose of RabAvert administered intramuscularly in the right arm, and on the same day, the patient was vaccinated with the co-suspect YF-VAX (Yellow Fever Vaccine Live) administered in the right arm, which is considered vaccination error. The patient experienced injection site erythema, injection site pain and injection site warmth two days after vaccination. The major confounding factor for the events is co-suspect vaccine (YF-VAX), administered on the same day. However, due to plausible temporal relationship and since contributory role of RabAvert cannot be excluded, the causality for the events of injection site erythema, injection site pain and injection site warmth is assessed as possibly related to the suspect vaccine. Vaccination error is not related to the suspect product, but to a decision of the prescribing physician. This case is considered non-serious.

Weitere VAERSDATA-Felder
Praegender Schweregrund
Injection site erythema
Hospital-Tage
-
Labordaten
-
Aktuelle Erkrankungen
-
Vorgeschichte
Comments: None
Andere Medikamente
AMITIZA; SYNTHYROID; SIMVASTATIN; MYRBETRIQ
Allergien
-
Vorherige Impfungen
-

VAERS 1526009

SANOFI PASTEUR · YELLOW FEVER (YF-VAX) · Charge UJ372AA

mild
Staat
NY
Alter
-
Geschlecht
F
Eingang
09.07.2022
Impfdatum
20.07.2021
Beginn
22.07.2021
Tage bis Beginn
2,0
Dosis
UNK
Route/Site
SC / RA
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: ja
Injection site erythema Injection site pain Injection site warmth Laboratory test normal

Symptomtext

RabAvert and YF-Vax administered at the same site; Pt. had redness, warmth and soreness at the injection site; Pt. had redness, warmth and soreness at the injection site; Pt. had redness, warmth and soreness at the injection site; Case reference number US-BN-2021-002299, initially downloaded from Vaccine Adverse Event Reporting System (VAERS) on 27-Sep-2021, is a spontaneous case received from consumer via health authority (VAERS ID: 1526009-1) and concerns a 64-year-old female patient. The patient's medical history details were not provided. The patient's concomitant medications included Amitiza (lubiprostone), Synthyroid (Levothyroxine sodium), simvastatin and Myrbetriq (Mirabegron). On 20-Jul-2021, patient was vaccinated with the first dose of RabAvert (Inactivated Rabies Virus Vaccine; batch number: ARBA571B), at an unknown dose, administered intramuscularly in the right arm, for an unknown indication. On the same date, the patient was vaccinated with the co-suspect YF-VAX (Yellow Fever Vaccine Live; batch number: UJ372AA), at an unknown dose, administered subcutaneously in the right arm, for an unknown indication (explicitly codes as ?Vaccination error'). On 22-Jul-2021 (also reported as on 23-Jul-2021), the patient experienced redness, warmth and soreness at the injection site. It was reported that the physician prescribed the patient Kepflex 500mg, BID for a five day course, although the patient didn't start the medication. On 24-Jul-2021, the patient visited Emergency Department, where she was prescribed Doxycycline 100 mg BID and had laboratory tests performed, with results reported as laboratory test normal. It was reported that the patient started with the Doxycycline medication. On 27-Jul-2021, the patient visited the clinic again, and it was reported that on examination the redness was lighter in colour, but that it spread a little bit more. On an unspecified date, the patient recovered from the events of injection site redness, injection site warmth and injection site pain. The case was assessed as not serious. Causality assessment was not provided. No further information was provided.; Reporter's Comments: Injection site erythema and injection site pain are listed for RabAvert according to the PI and Prescriber Information, whilst injection site warmth is unlisted. Vaccination error is listed per convention. The patient was vaccinated with the first dose of RabAvert administered intramuscularly in the right arm, and on the same day, the patient was vaccinated with the co-suspect YF-VAX (Yellow Fever Vaccine Live) administered in the right arm, which is considered vaccination error. The patient experienced injection site erythema, injection site pain and injection site warmth two days after vaccination. The major confounding factor for the events is co-suspect vaccine (YF-VAX), administered on the same day. However, due to plausible temporal relationship and since contributory role of RabAvert cannot be excluded, the causality for the events of injection site erythema, injection site pain and injection site warmth is assessed as possibly related to the suspect vaccine. Vaccination error is not related to the suspect product, but to a decision of the prescribing physician. This case is considered non-serious.; Sender's Comments: Injection site erythema and injection site pain are listed for RabAvert according to the PI and Prescriber Information, whilst injection site warmth is unlisted. Vaccination error is listed per convention. The patient was vaccinated with the first dose of RabAvert administered intramuscularly in the right arm, and on the same day, the patient was vaccinated with the co-suspect YF-VAX (Yellow Fever Vaccine Live) administered in the right arm, which is considered vaccination error. The patient experienced injection site erythema, injection site pain and injection site warmth two days after vaccination. The major confounding factor for the events is co-suspect vaccine (YF-VAX), administered on the same day. However, due to plausible temporal relationship and since contributory role of RabAvert cannot be excluded, the causality for the events of injection site erythema, injection site pain and injection site warmth is assessed as possibly related to the suspect vaccine. Vaccination error is not related to the suspect product, but to a decision of the prescribing physician. This case is considered non-serious.

Weitere VAERSDATA-Felder
Praegender Schweregrund
Injection site erythema
Hospital-Tage
-
Labordaten
-
Aktuelle Erkrankungen
-
Vorgeschichte
Comments: None
Andere Medikamente
AMITIZA; SYNTHYROID; SIMVASTATIN; MYRBETRIQ
Allergien
-
Vorherige Impfungen
-

VAERS 2161882

SANOFI PASTEUR · YELLOW FEVER (YF-VAX) · Charge UJ372AA

gering
Staat
OH
Alter
-
Geschlecht
U
Eingang
05.03.2022
Impfdatum
25.02.2022
Beginn
25.02.2022
Tage bis Beginn
0,0
Dosis
UNK
Route/Site
OT / -
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: nein
Expired product administered Medication error No adverse event

Symptomtext

patient was given YF-vax today but the diluent was expired with no adverse event; Initial information received on 25-Feb-2022 regarding an unsolicited valid non-serious case received from a pharmacist. This case involves an patient of unknown demographics who was given yf-vax today but the diluent was expired with no adverse event while receiving Yellow Fever Vaccine- US [YF-VAX]. The patient's past medical history, medical treatment(s), vaccination(s) and family history were not provided. On 25-Feb-2022, the patient received a dose of suspect YF-VAX (strength, dose, route, administration site: unknown, Lot Number: UJ372AA, Expiration Date: 22-Jul-2022) for immunization. It was reported that Diluent of the YF-VAX had expired (Lot Number: U6428AA, Expiration Date: 09-Sep-2021). On 25-Feb-2022 the patient was given YF-VAX but it was reported that the diluent was expired with no adverse event (expired product administered) (Latency: same day). Action taken was not applicable. Outcome was Unknown. This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in the guidelines. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.

Weitere VAERSDATA-Felder
Praegender Schweregrund
Expired product administered
Hospital-Tage
-
Labordaten
-
Aktuelle Erkrankungen
-
Vorgeschichte
-
Andere Medikamente
-
Allergien
-
Vorherige Impfungen
-

VAERS 1961676

SANOFI PASTEUR · YELLOW FEVER (YF-VAX) · Charge UJ372AA

gering
Staat
CA
Alter
-
Geschlecht
U
Eingang
18.12.2021
Impfdatum
-
Beginn
-
Tage bis Beginn
-
Dosis
UNK
Route/Site
OT / -
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: nein
Expired product administered

Symptomtext

patient were administered the Yellow Fever vaccine with the expired diluent, with no reported adverse event; Initial information received on 10-Dec-2021 regarding an unsolicited valid non-serious case received from an other healthcare professional via call center via regulatory agency (Reference number- 00893306). This case involves a patient of (unknown demographics) who was vaccinated with an expired dose of suspect YELLOW FEVER VACCINE - US [YF-VAX] (expired product administered). The patient's medical history, medical treatments, vaccinations, concomitant medication and family history were not provided. On an unknown date, the patient received a dose of suspect YELLOW FEVER VACCINE - US (Vaccine: lot number: UJ372AA and expiry date: 22-Jun-2022 and Diluent: lot number: U6427AA and expiry date: 30-Sep-2021) via an unknown route at an unknown administration site for prophylactic vaccination. It was an actual medication error case due to expired vaccine used (latency: same day). It was reported "Caller stated that the sodium chloride diluent that goes with the vaccine expired and was administered to patients after expiration date. Caller asking if the diluent would still be stable and what should be done. She asks if they were valid doses or if they need to be repeated. She asks if Yellow Fever Vaccine is a live vaccine and how long they need to wait to revaccinate the patients involved." At the time of reporting, no adverse event was reported. This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in guidelines. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.

Weitere VAERSDATA-Felder
Praegender Schweregrund
Expired product administered
Hospital-Tage
-
Labordaten
-
Aktuelle Erkrankungen
-
Vorgeschichte
-
Andere Medikamente
-
Allergien
-
Vorherige Impfungen
-

VAERS 1512068

SANOFI PASTEUR · YELLOW FEVER (YF-VAX) · Charge UJ372AA

gering
Staat
MA
Alter
47,0
Geschlecht
F
Eingang
29.07.2021
Impfdatum
16.07.2021
Beginn
16.07.2021
Tage bis Beginn
0,0
Dosis
UNK
Route/Site
OT / LA
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: nein
Medication error No adverse event Product preparation issue

Symptomtext

instead of using sodium chloride to mix YF VACCINE with they mixed the vaccine with sterile water, no AE; Initial information regarding an unsolicited valid non-serious case was received from other healthcare professional via Agency (Reference number- 00688211) and transmitted to Sanofi on 19-Jul-2021. This case involves a 47-year-old female patient who was administered YELLOW FEVER VACCINE - US [YF-VAX] in which instead of using sodium chloride to mix, they mixed the vaccine with sterile water (product preparation issue). The patient's medical history, past medical treatment(s), vaccination(s), concomitant medications and family history were not provided. On 16-Jul-2021, the patient received 0.5 mL dose of suspect YELLOW FEVER VACCINE - (lot UJ372AA and expiry date: 22-Jul-2022) via a subcutaneous route in the left arm for prophylactic vaccination in which instead of using sodium chloride to mix, they mixed the vaccine with sterile water (product preparation issue). It was reported that "She wanted to the implications as it has already been administered. Caller transferred. Caller asking how to proceed if Yellow Fever Vaccine was given to 2 patients mixed with the diluent that is used for MMR and Varicella vaccines, it is sterile water. Caller asking why do they need to revaccinate? Do you have any specific data showing that the sterile water that they used makes the vaccine not work or stable? She asked if this is a general CDC statement or specific to YF vaccine? Does Sanofi Pasteur have actual data showing why the specific diluent is the only one that can be used? Caller said they have to investigate more and therefore this doctor is not 100% verified as the person involved in this event) medical assistant (MA) who administered vaccine. Caller came back and said she gave all this information before she checked with her medical director and she would like to wait for the medical director to make the report after they have fully investigated what happened. Medical director will be back in the office next week." It was a actual case of medication error due to Inappropriate reconstitution technique (latency same day). At time of reporting, no adverse events were reported. This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in the Directive 2001/83/EC and Module VI of the Good Pharmacovigilance Practices. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error

Weitere VAERSDATA-Felder
Praegender Schweregrund
Medication error
Hospital-Tage
-
Labordaten
-
Aktuelle Erkrankungen
-
Vorgeschichte
-
Andere Medikamente
-
Allergien
-
Vorherige Impfungen
-

VAERS 1442718

SANOFI PASTEUR · YELLOW FEVER (YF-VAX) · Charge UJ372AA

gering
Staat
VA
Alter
23,0
Geschlecht
F
Eingang
02.07.2021
Impfdatum
23.06.2021
Beginn
23.06.2021
Tage bis Beginn
0,0
Dosis
UNK
Route/Site
OT / -
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: nein
Device breakage Dry eye Eye irritation Occupational exposure to product

Symptomtext

both eyes feel dry; both eyes feel irritated; While getting the YF vaccine ready to administer the orange clasp broke off while pressing the middle part to get the air out and sprayed in eye; while getting the YF vaccine ready to administer the orange clasp broke off while pressing the middle part to get the air out and sprayed in eye; Initial information was received on 24-Jun-2021 regarding an unsolicited valid non-serious case from an other-health care professional (Inquiry number: 00654896). This case involves a 23-years-old female health professional whose eye got sprayed with 0.5 ml YELLOW FEVER VACCINE - [YF-VAX] (lot number: UJ372AA, expiration date: 22-Jul-2022) while administration, as the orange clasp broke off while pressing the middle part to get the air out (Occupational exposure to product and Device breakage) on 23-Jun-2021. The patient's past medical history, medical treatment(s), vaccination(s), concomitant medication(s) and family history were not provided. It was a case of an actual medication error due to occupational exposure to product via eye and device breakage (latency same day). On 24-Jun-2021, the patient developed a non-serious event of both eyes dry and feel irritated (Dry eye and Eye irritation) (1 day) following the administration of YELLOW FEVER VACCINE - [YF-VAX]. The caller reported that while she was getting the YF VACCINE ready to administer, "the orange clasp broke off and while pressing the middle part to get the air out it broke off and sprayed in callers eye." The caller wanted to know if there was something she should do for her eye. There is no noticeable irritation, but it feels irritated. Yesterday (23 Jun 2021) at about 4 pm, the HCP was preparing a YF-VAX dose, and had it in a syringe, and the orange part that you turn on the syringe, which is supposed to be tight, was loose, and the YF-VAX sprayed out from the middle of the syringe, not from the needle, and sprayed into both of her eyes. HCP stated that she flushed her eyes out with water after this happened. HCP stated that she did not experience any symptoms yesterday for a few hours, but today (24 Jun 2021) both eyes feel dry and irritated. HCP had a doctor there look at her eyes, and they are not red. Patient stated that she is not currently experiencing any systemic side effects, just the dryness and irritation of both eyes. No relevant laboratory data was reported. It was unknown if patient received a corrective treatment for the events. The patient had not recovered from the reported events dry eye and eye irritation. This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in Directive 2001/83/EC and Module VI of the Good Pharmacovigilance Practices. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error

Weitere VAERSDATA-Felder
Praegender Schweregrund
Device breakage
Hospital-Tage
-
Labordaten
-
Aktuelle Erkrankungen
-
Vorgeschichte
-
Andere Medikamente
-
Allergien
-
Vorherige Impfungen
-

VAERS 1440114

SANOFI PASTEUR · YELLOW FEVER (YF-VAX) · Charge UJ372AA

gering
Staat
MD
Alter
2,0
Geschlecht
F
Eingang
01.07.2021
Impfdatum
18.05.2021
Beginn
-
Tage bis Beginn
-
Dosis
UNK
Route/Site
OT / RL
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: nein
Alopecia Autoimmune disorder

Symptomtext

exacerbate autoimmune issues with hair loss; exacerbate autoimmune issues with hair loss; alopecia/ hair loss; Initial information was received on 21-Jun-2021 regarding an unsolicited valid serious case from a physician. This case involves a two-year-old female patient who had a exacerbate autoimmune issues with hair loss (autoimmune disorder with symptom of alopecia), after she received MENINGOCOCCAL A-C-Y-W135 (D CONJ) VACCINE [MENACTRA], TYPHOID VI POLYSACCHARIDE VACCINE [TYPHIM VI] and YELLOW FEVER VACCINE - US [YF-VAX]. Medical history, medical treatment, vaccination and family history were not provided. Concomitant medications included MEFLOQUINE HYDROCHLORIDE (LARIAM) (1/4 tab weekly) and MEASLES VACCINE, MUMPS VACCINE, RUBELLA VACCINE (MMR) was administered via arm. On 18-May-2021, the patient received a dose of suspect MENINGOCOCCAL A-C-Y-W135 (D CONJ) VACCINE [lot number and expiry date not reported] via an unknown route at an unknown administration site for prophylactic vaccination. On 10-Jun-2021, the patient received a 0.5 ml dose of suspect YELLOW FEVER VACCINE - US [lot number: UJ372AA, expiry date not reported] via subcutaneous route at right thigh for prophylactic vaccination. On 10-Jun-2021, the patient received a 0.5 ml dose of suspect TYPHOID VI POLYSACCHARIDE VACCINE [lot number: T1A671M, expiry date not reported] via subcutaneous route at right thigh for prophylactic vaccination. On an unknown date the patient had a serious exacerbate a potential autoimmune issue with hair loss (autoimmune disorder, condition aggravated with symptom of alopecia), (unknown latency) following the administration of YELLOW FEVER VACCINE - US, TYPHOID VI POLYSACCHARIDE VACCINE and MENINGOCOCCAL A-C-Y-W135 (D CONJ) VACCINE. These event was assessed as medically significant. Details of laboratory data were not reported. It was not reported if the patient received a corrective treatment for the events. At the time of reporting, the patient's father was asking if theses vaccines could exacerbate a potential autoimmune issue with hair loss that his daughter is experiencing. At the time of reporting, the event outcomes were unknown.; Sender's Comments: This case involves a two-year-old female patient who experienced exacerbated autoimmune issues with hair loss after vaccination with MENACTRA, TYPHIM VI and YF-VAX. The time to onset was unknown. Concomitant medications included LARIAM and MEASLES VACCINE, MUMPS VACCINE, RUBELLA VACCINE. Further information regarding concurrent condition during vaccination, previous vaccination and tolerance, laboratory investigations excluding alternative etiologies for the reported event are needed to fully assess this case. Based upon the reported information, the role of the suspect vaccines cannot be assessed.

Weitere VAERSDATA-Felder
Praegender Schweregrund
Alopecia
Hospital-Tage
-
Labordaten
-
Aktuelle Erkrankungen
-
Vorgeschichte
-
Andere Medikamente
LARIAM; MMR
Allergien
-
Vorherige Impfungen
-